Axel Mescheder, CMO, to present an update on phase III, registrational trial of emactuzumab for patients suffering with TGCT (TANGENT) Professor David Kerr, FRCP, to present on “Emactuzumab: Target Mediated Drug Disposition” CTOS virtual Annual Meeting 10-13 November 2021 Dublin, Ireland, November 12, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical…
SynOx Therapeutics Limited is a late-stage clinical biopharmaceutical company registered in Ireland.
In November 2020, SynOx acquired from Roche an exclusive worldwide licence to emactuzumab, a potentially best-in-class CSF-1R therapeutic antibody.
Emactuzumab has a well-tolerated safety profile and showed remarkable efficacy in patients suffering from diffuse Tenosynovial Giant Cell Tumours (TGCT), a rare disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.